This inventor holds 2 USPTO granted patents, plus 3 CIPO patents and 1 EPO patent. Top assignee: Abraxis Bioscience, LLC. Active years: 2013-2015.
Location History:
- Costa Mesa, CA (US) (2013)
- Fairfield, NJ (US) (2015)
Company Filing History:
Years Active: 2013-2015
Title: The Innovations of Daniel Knauer
Introduction
Daniel Knauer is an accomplished inventor based in Fairfield, NJ (US). He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of 2 patents, his work focuses on improving the efficacy of chemotherapy through innovative techniques.
Latest Patents
Knauer's latest patents include groundbreaking inventions that utilize anti-SPARC antibodies. The first patent, titled "Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma," provides techniques for predicting how patients will respond to chemotherapy. The second patent, "Use of 2 anti-SPARC antibodies to predict response to melanoma chemotherapy," similarly offers methods for predicting chemotherapy responses in melanoma patients. These inventions represent a significant advancement in personalized medicine.
Career Highlights
Daniel Knauer is currently associated with Abraxis Bioscience, LLC, where he continues to develop innovative solutions in cancer treatment. His work has garnered attention for its potential to enhance patient outcomes through tailored therapeutic approaches.
Collaborations
Knauer has collaborated with notable colleagues, including Vuong Trieu and Neil P Desai. Their combined expertise contributes to the advancement of research and development in the field of oncology.
Conclusion
Daniel Knauer's contributions to cancer treatment through his patented inventions highlight the importance of innovation in medicine. His work not only aims to improve patient care but also sets a precedent for future research in the field.